Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) had its price target dropped by Piper Sandler from $7.00 to $5.00 in a report released on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s target price would suggest a potential upside of 461.80% from the company’s current price. Other equities […]
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
Selinexor is under clinical development by Karyopharm Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.
-- Conference Call Scheduled for Thursday, November 2, 2023, at 8:00 a.m. ET -- NEWTON, Mass., Oct. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 16,640,000 shares, a growth of 10.6% from the September 15th total of 15,040,000 shares. Based on an average trading volume of 2,150,000 shares, the days-to-cover ratio […]